Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiachen Xu(Wenzhou Medical University), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Lan(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuelian Chen(Chengdu Medical College), Xingyuan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Dawei Wu(Chinese PLA General Hospital), Dong Qu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianping Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Honggang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qing Yang(Guangzhou University of Chinese Medicine)
British Journal of Cancer
May 10, 2018
10.1038/s41416-018-0100-3
Cited by 156

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821